I do wonder what Takeda's thinking with how PAT-SM6 has been delivering in trials, ODD approved in multiple jurisdictions & of course moving to the combination trial with Kyprolis.
They still have their own market share in Velcade to protect with Kprolis now entering market & Celgene stamping its dominance all over the place. While not a huge position Takeda's venture arm still sits in Patrys Top 20 as at the last Annual Report.
Maslow Fast Track can come before completion of Phase II it can even come prior to starting a Phase II trial just look at when NEU got Fragile X Fast Tracked.
PAB Price at posting:
4.8¢ Sentiment: None Disclosure: Held
